Over 280,000 receive COVID-19 vaccines in Bulacan | Inquirer News

Over 280,000 receive COVID-19 vaccines in Bulacan

By: - Correspondent / @inquirerdotnet
/ 01:59 PM July 03, 2021

CITY OF MALOLOS — More than 280,000 residents of Bulacan province are now vaccinated as the province intensifies its fight against the coronavirus disease (COVID-19), the Bulacan provincial information office said Friday.

The agency said 283,487 of A1, A2, A3, and A4 beneficiaries were vaccinated, of which 222,963 or 95 percent had their first dose and 60,524 or 28 percent are now fully vaccinated.

Article continues after this advertisement

Pat Alvaro, Bulacan Public Health Office information officer said there are now 767,351 residents who have registered for vaccination. The province has an average daily vaccination of 83,621.

With more than 3.2 million residents, Bulacan can achieve herd immunity with about 2 million people getting vaccinated.

Bulacan’s COVID-19 cases have reached 40,702 on Saturday, with 39,048 recoveries and 876 deaths since the pandemic broke out in March last year.

/MUF
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Bulacan, COVID-19, Vaccination

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.